Recent Quotes (30 days)

You have no recent quotes
chg | %

Finance

Results 1 - 8 of about 8 for DANIEL J. BARRETT
Company Exchange Symbol Last price Quote change Market cap
Cutera, Inc. NASDAQ CUTR 10.72 +0.08 (0.75%) 137.52M
Cutera, Inc. is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other ...
Executive:
J. Daniel Plants
Carolina Bank Holding Inc. (NC) NASDAQ CLBH 18.49 +0.03 (0.16%) 93.29M
Carolina Bank Holdings, Inc. is a bank holding company of the Carolina Bank (the Bank). The Bank engages in a general banking business in Guilford, ...
Executive:
Daniel D. Hornfeck
Babson Capital Corporate Investors NYSE MCI 18.19 0.00 (0.00%) 358.25M
Babson Capital Corporate Investors (the Trust) is a closed-end management investment company. The Trust's investment objective is to maintain a portfolio of ...
Executive:
Daniel J. Florence
Clovis Oncology Inc NASDAQ CLVS 13.96 +0.05 (0.36%) 525.29M
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, ...
Executive:
Daniel Muehl
Babson Capital Participation Investors NYSE MPV 14.89 +0.08 (0.54%) 152.76M
Babson Capital Participation Investors (the Trust) is a closed-end management investment company. The Trust's investment objective is to maximize total ...
Executive:
Daniel J. Florence
Dawson Geophysical Co NASDAQ DWSN 7.66 +0.39 (5.36%) 153.40M
Dawson Geophysical Company, formerly TGC Industries, Inc., is a provider of onshore seismic data acquisition and processing services with operations ...
Executive:
Daniel G. Winn
Zafgen Inc NASDAQ ZFGN 3.09 -0.03 (-0.96%) 89.13M
Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex ...
Executive:
Thomas O. Daniel MD.
GlycoMimetics Inc NASDAQ GLYC 8.56 -0.04 (-0.47%) 204.72M
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs.
Executive:
Daniel M. Junius